Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01482949
Other study ID # AGS-003-005
Secondary ID
Status Terminated
Phase Phase 2
First received
Last updated
Start date September 2011
Est. completion date May 2018

Study information

Verified date June 2018
Source Argos Therapeutics
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate clinical response to AGS-003 alone or in combination with sunitinib therapy.


Description:

AGS-003-005 is a rollover, open label, Phase II clinical study testing the biologic activity and safety of AGS-003 in subjects who have experienced either partial responses or prolonged stable disease and continue to benefit from ongoing treatment with AGS-003 in protocols AGS-003-004 or AGS-003-006.

Rollover subjects from AGS-003-004 will continue with AGS-003 monotherapy booster dosing until disease progression or until a discontinuation criterion is reached.

Subjects that progress on AGS-003 monotherapy (from the AGS-003-004 protocol) may start sunitinib treatment and re-initiate AGS-003 therapy beginning with the induction phase dosing schedule.

Rollover subjects from AGS-003-006 will continue sunitinib dosing in combination with booster dosing of AGS-003 until disease progression or until a discontinuation criterion is reached.

If a subject has disease progression due to a new tumor lesion, upon consultation between the investigator, Argos representatives and the Argos medical monitor, the subject may be considered for re-manufacture of study product (from the new metastatic lesion) and dosing with this new product in combination with sunitinib beginning with the induction phase dosing schedule.

For those subjects initiating treatment with the induction phase as described above, restaging imaging occurs at screening (baseline), prior to the fifth dose in the induction phase (as applicable) and every 12 weeks during the booster phase (at the start of the sunitinib holiday, 2 weeks prior to the next AGS-003 dose).

For subjects on combination therapy, if dosing with sunitinib is stopped due to sunitinib-related issues, treatment with AGS-003 may continue.

Close-out visits will occur upon disease progression (other than circumstances discussed above which are eligible for re-induction) or upon decision to terminate the study by the sponsor.

Quarterly follow-up for survival for each subject will occur by telephone interview for 1 year following the last AGS-003 administration or study termination.


Recruitment information / eligibility

Status Terminated
Enrollment 2
Est. completion date May 2018
Est. primary completion date May 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Age = 18 years

- Subjects are receiving ongoing treatment with AGS-003 in protocol AGS- 003-004 or AGS-003-006.

- Measurable disease that can be monitored per RECIST throughout the course of study participation.

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

- Adequate hematologic function, as defined by the following criteria:

1. White blood cell (WBC) = 4000/µL (= 4.0 x 103/µL)

2. Absolute neutrophil count (ANC) = 1500/µL (= 1.5 x 103/µL)

3. Platelets = 100,000/µL (= 100 x 103/µL)

4. Hemoglobin (Hgb) = 9.0 g/dL

- Adequate renal and hepatic function, as defined by the following criteria:

1. Serum creatinine = 1.5 x upper limit of normal (ULN) or, if serum creatinine > 1.5 x ULN, estimated glomerular filtration rate (eGFR) = 30 mL/min

2. Total serum bilirubin = 1.5 x ULN

3. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = 2.5 x ULN, or AST and ALT = 5 x ULN if liver function abnormalities are due to underlying malignancy

- Adequate coagulation function as defined by the following criteria:

1. Prothrombin time (PT) = 1.5 x ULN

2. Activated partial thromboplastin time (PTT) < 1.5 x ULN

3. Corrected calcium = 11.5 mg/dL

- Negative serum pregnancy test for female subjects with reproductive potential, and agreement of all male and female subjects of reproductive potential to use a reliable form of contraception during the study and for 12 weeks after the last dose of study drug

- Able to abstain from taking prohibited drugs, either prescription or non- prescription, during the treatment phase of the study

- Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures

- Signed and dated informed consent document indicating that the subject (or legally acceptable representative) has been informed of all pertinent aspects of the trial prior to enrollment

- No brain metastases detected by magnetic resonance imaging (MRI).

Exclusion Criteria:

- Any serious medical condition considered by the investigator to constitute an unwarranted high risk for investigational treatment

- History of or known brain metastases, spinal cord compression, or carcinomatous meningitis, or evidence of brain or leptomeningeal disease on screening computed tomography (CT) scan or MRI

- Pregnancy or breastfeeding

- Active autoimmune disease or condition requiring chronic immunosuppressive therapy

NOTE: Abnormal laboratory values for autoimmunity markers in the absence of other signs/symptoms of autoimmune disease are not exclusionary.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
AGS-003
Autologous Dendritic Cell Immunotherapy

Locations

Country Name City State
United States University of Minnesota Cancer Center Minneapolis Minnesota

Sponsors (1)

Lead Sponsor Collaborator
Argos Therapeutics

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Tumor response Clinical antitumor activity of AGS-003 will be assessed as an objective tumor response by Response Evaluation Criteria in Solid Tumors (RECIST). From date of registration until either disease progression, meeting a discontinuation criterion, or death; assessed up to 36 months.
Secondary Clinical benefit (stable disease or response) Clinical benefit measured as Stable Disease (SD), Partial Response (PR), and Complete Response (CR) rate to the treatment regimen. Tumor response is verified using standard definitions of RECIST From date of registration until either disease progression, meeting a discontinuation criterion, or death; assessed up to 36 months.
Secondary Immune function Analyses of immune function will be performed. This will include, but not limited to, assessment of T cell and antigen presenting cell populations, including effector memory, cytotoxic lymphocytes (CTLs), and regulatory T cells. Blood and plasma specimens for these analyses will be collected at specified time points and is optional for subjects continuing with booster treatments. From date of registration until either disease progression, meeting a discontinuation criterion, or death; assessed up to 36 months.
Secondary Progression Free Survival (PFS) Evaluate PFS from the date of registration until PFS is reached per RECIST From date of registration until either disease progression, meeting a discontinuation criterion, or death; assessed up to 36 months.
Secondary Overall Survival (OS) Evaluate OS from date of registration until date of death. From date of registration until either disease progression, meeting a discontinuation criterion, or death; assessed up to 36 months.
Secondary Treatment-emergent Adverse Events Monitor incidence of treatment-emergent Adverse Events. From date of registration until either disease progression, meeting a discontinuation criterion, or death; assessed up to 36 months.
Secondary Monitor clinical chemistry, hematology, and urinalysis for treatment-emergent changes from baseline Clinical laboratory values will be monitored for changes from baseline. From date of registration until either disease progression, meeting a discontinuation criterion, or death; assessed up to 36 months.
Secondary Physical Examinations Monitor changes from baseline in physical examinations From date of registration until either disease progression, meeting a discontinuation criterion, or death; assessed up to 36 months.
Secondary Vital Signs Monitor changes from baseline in vital signs From date of registration until either disease progression, meeting a discontinuation criterion, or death; assessed up to 36 months.
Secondary Monitor signs and symptoms indicating treatment-emergent autoimmunity Autoimmunity evaluations will be measured by clinical signs and symptoms (e.g., rash, cytopenias, and arthralgias) and by laboratory assessments. These assessments will be monitored as long as the subject is receiving AGS-003. From date of registration until either disease progression, meeting a discontinuation criterion, or death; assessed up to 36 months.
Secondary Monitor for lymph node adenopathy The draining lymph nodes (axillary and inguinal) will be evaluated for changes from baseline in size, tenderness, or inflammation. These assessments will be monitored as long as the subject is receiving AGS-003. From date of registration until either disease progression, meeting a discontinuation criterion, or death; assessed up to 36 months.
Secondary Injection Site Reaction Monitor changes from baseline in injection site reactions. From date of registration until either disease progression, meeting a discontinuation criterion, or death; assessed up to 36 months.
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04987203 - Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Phase 3
Recruiting NCT06391879 - Establishment of a Multidimensional Prediction Model for the Natural Course of VHL Disease-related Renal Cell Carcinoma
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Recruiting NCT05059444 - ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Terminated NCT03655613 - APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC Phase 1/Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Withdrawn NCT05418387 - A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona N/A
Recruiting NCT04623502 - An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy N/A
Completed NCT02853344 - Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427) Phase 2
Terminated NCT04088500 - A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma Phase 2
Completed NCT05070637 - Circulating Tumor Cell Reducing No-touch Nephrectomy N/A
Active, not recruiting NCT03634540 - A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003) Phase 2
Not yet recruiting NCT06049030 - A Study of HS-10516 in Patients With Advanced Clear Cell Renal Cell Carcinoma Phase 1
Completed NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Completed NCT01358721 - Phase I Biomarker Study (BMS-936558) Phase 1
Active, not recruiting NCT04503148 - Anesthesia and Cancer Study: Renal Cell Carcinoma N/A
Completed NCT02386826 - INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme Phase 1
Not yet recruiting NCT05808608 - A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma Phase 1/Phase 2
Withdrawn NCT03323710 - Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell Carcinoma Phase 2
Completed NCT03052504 - Prospective Versus Retrospective Complications in Radical Cystectomy and Nephrectomy